Psychiatric Genomics of Gaithersburg, Md., which uses gene expression analysis of brain and other human tissues to develop medications for mental illness, has appointed Bradley Lorimier to its board of directors and as a business development consultant. Lorimer currently consults within the pharmaceutical industry and serves on the boards of four companies. Lorimer retired from his position as senior vice president of business development for Human Genome Sciences in 1997. Before joining HGS, Lorimer also served in management positions at Johnson & Johnson, Sterling Drug, and Revlon Health Care Group.
Sprout Group, a venture capital affiliate of Credit Suisse First Boston, has hired former GlaxoSmithKline chief science and technology officer James Niedel as a partner for health-care technology investments. Between 1995 and 2001, Niedel oversaw global R&D, information technology, and product strategy at GlaxoWellcome.